Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Potential prognostic markers in sarcomatoid and rhabdoid RCC

Ziad Bakouny • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Nivolumab

Ziad Bakouny, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the genomic characterization of sarcomatoid and rhabdoid renal cell carcinoma (RCC) to reveal potential markers of poor prognosis and response to immune checkpoint inhibition. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Ziad Bakouny

4:31
Cytoreductive nephrectomy for RCC
Ziad Bakouny • 13 Feb 2020
2:41
Translational approaches in immunotherapy
Ziad Bakouny • 15 Feb 2020
3:03
Next-gen immuno-oncology therapies in RCC
Ziad Bakouny • 14 Feb 2020

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals